Stoke Therapeutics, Inc. (STOK) Misses Q3 EPS by 7c

Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q3 EPS of ($0.65), $0.07 worse than the analyst estimate of ($0.58). Revenue for the quarter came in at $10.63 million versus the consensus estimate of $6.06 million.

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.

You May Also Be Interested In

• Paramount Weighs Tapping Musk For Equity Investment - Semafor
• General Mills beats estimates as cost savings offset volumes
• Scotiabank Reiterates Sector Outperform Rating on Ero Copper Corp. (ERO:CN) (ERO)